Mironid

Investor: Scottish National Investment Bank, Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, University of Strathclyde

Mironid, a Glasgow-based biopharmaceutical company specializing in therapeutics for Autosomal Dominant Polycystic Kidney Disease (ADPKD), has successfully completed a Series B funding round, securing £34 million to further the clinical development of its lead small molecule therapeutic.Summary of transaction details:Value: £34 millionSector: Healthcare & BiotechAdvisor: Not specifiedKey Entities: Mironid (Target), Scottish National Investment Bank, Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, University of Strathclyde (Investors)Location: Glasgow, UK (Target company)Note: This significant capital injection will enable Mironid to accelerate the clinical trials of its first-in-class LoAc small molecules, which are designed to directly target cyclic AMP and address a critical unmet need for patients suffering from ADPKD, a rare hereditary kidney disorder.

Investor: Scottish Investment Bank - Scottish Enterprise, Epidarex Capital